Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (ATRA)
NASDAQ:ATRA
ATRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.40 - $20.82
Previous CloseN/A
Volume32.09K
Average Volume (3M)67.15K
Market Cap
$40.66M
Enterprise Value$81.44M
Total Cash (Recent Filing)$25.03M
Total Debt (Recent Filing)$43.83M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 07, 2025EPS Estimate
-2.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.87
Shares Outstanding5,858,909
10 Day Avg. Volume61,946
30 Day Avg. Volume67,148
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.30
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap2.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.75
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$9.00Price Target Upside30.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Atara Biotherapeutics News
See All ATRA News
---
Bulls Say, Bears Say
Bulls Say
Financial SupportAtara has entered into a non-binding term sheet with Redmile Group to provide up to $15M in funding through an equity line of credit.
Manufacturing ApprovalA second third-party manufacturer FUJIFILM Diosynth Biotechnologies (FDB) has recently been approved to manufacture Ebvallo for EMA, supporting the overall manufacturing process.
Regulatory ProgressAtara is laser focused on resubmitting BLA for Ebvallo approval in US.
Bears Say
Financial ConstraintsDue to current capital constraints, ATRA has paused the '3219/'3431 CAR-T programs and cut headcount.
Operational ChallengesAtara announced a reduction in its workforce that will impact approximately 50% of its current employees.
Regulatory SetbacksThe recent Complete Response Letter (CRL) for EBVALLO and the FDA's cessation of several trials linked to the rejection of the EBVALLO application.
---
Ownership Overview
33.45% Insiders
7.11% Mutual Funds
21.57% Other Institutional Investors
34.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $5.40 and its highest was $20.82 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is $40.66M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is May 07, 2025 which is in 42 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Mar 07, 2025. The company reported -$1.19 earnings per share for the quarter, beating the consensus estimate of -$2.861 by $1.671.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -2.33.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 5,858,909 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$1.19 in its last earnings report, beating expectations of -$2.861. Following the earnings report the stock price went down -10.725%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at 0.
---
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (30.06% Upside)
$9.00 (30.06% Upside)
Blogger Sentiment
Bullish
ATRA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $31.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.19%
12-Months-Change
Fundamentals
Return on Equity
1063.61%
Trailing 12-Months
Asset Growth
-34.08%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
---
ATRA Stock 12 Month Forecast
Average Price Target
$9.00
▲(30.06% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Cara Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering ATRA
1 Year
1 Year Success Rate
16/41 ratings generated profit
1 Year Average Return
-5.65%
reiterated a buy rating 17 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 39.02% of your transactions generating a profit, with an average return of -5.65% per trade.
---